azh-biotics® – How Does Microbiome Science Support People on GLP-1 Weight Journeys?
AZH-biotics® is a Swiss-developed, European-manufactured probiotic, specifically designed to support individuals using GLP-1 medications such as Ozempic, Wegovy, Zepbound, Mounjaro, and Rybelsus.
The flagship innovation from Azento Health, AZH-biotics® combines high potency, patented strains, and a research-driven formulation to provide targeted support for gut health and nutrient absorption, while reducing common GLP-1 gastrointestinal side effects, helping patients stay on track with their therapy.
What Is AZH-biotics® and How Does It Work?
AZH-biotics® is a high-strength probiotic, developed specifically to support individuals using GLP-1 (glucagon-like peptide-1) receptor agonists, medications such as Wegovy, Mounjaro, or Ozempic, as part of their health and weight management journey.
GLP-1 therapies are clinically proven to aid weight loss by suppressing appetite, slowing digestion, and delaying gastric emptying. While effective in helping patients reduce calorie intake and achieve significant weight loss, these same mechanisms often disrupt the digestive system, particularly in the early stages of treatment.
Common gastrointestinal (GI) side effects include nausea, vomiting, bloating, constipation, and diarrhoea. In fact, real-world evidence suggests that up to 70% of GLP-1 users experience discomfort of varying intensity, and for many, these unpleasant symptoms reduce quality-of-life and can be severe enough to cause treatment discontinuation before their health goals are met.
Reduced food intake and changes in gut motility can also compromise the gut microbiome, disrupting microbial diversity, and weakening the gut barrier. Additionally, this can reduce the production of short-chain fatty acids (SCFAs), crucial compounds that help regulate inflammation, support gut lining integrity, and influence appetite and energy balance.
AZH-biotics® is formulated to address these challenges directly:
- Restores microbiota balance and healthy motility. 83% of users report GLP-1 side-effect relief.
- Helps maintain microbiome diversity and SCFA production during restricted food intake.
- Enhances satiety signalling, reduces cravings, and supports ongoing success with GLP-1 therapy.
- Facilitates absorption of crucial nutrients, especially minerals like calcium, magnesium, and zinc.
- Helps suppress pathogenic bacteria that can disrupt digestive processes.
AZH-biotics®
Each full daily dose of AZH-biotics® delivers 80 billion CFU (colony-forming units) of four proprietary, scientifically validated probiotic strains carefully selected for their targeted benefits:
- Bifidobacterium lactis AZHx1 (45 billion CFU): supports micronutrient absorption, strengthens the gut barrier, and reduces inflammation in the digestive tract.
- Lactobacillus casei AZHx3 (15 billion CFU): contributes to stress resilience, supports healthy gut motility, and enhances immune function.
- Lactobacillus rhamnosus GG (15 billion CFU): one of the most researched probiotic strains worldwide; helps protect the gut lining and reduce the risk of diarrhoea.
- Lactobacillus reuteri AZHx2 (5 billion CFU): promotes immune balance and digestive comfort; derived from the clinically validated DSM 17938 lineage.
Manufacturing and Quality Assurance
Each AZH-biotics® probiotic strain is verified through:
- Genotypic testing (e.g. 16S rRNA sequencing) to confirm precise identity of the strain.
- Phenotypic functional testing to validate expected behavior—such as resilience and ability to produce key compounds like SCFAs.
This two-step validation ensures each strain performs as intended.
The strains are patent-protected, manufactured in EU GMP-certified facilities under strict quality control—including testing for CFUs, contaminants (Salmonella, E. coli, heavy metals), allergens, and compliance with EU food supplement regulations (Directive 2002/46/EC). AZH-biotics® is free from dairy, gluten, soy, and GMOs.
Benefits for GLP-1 Users and Beyond
AZH-biotics® helps users on GLP-1 therapy by replenishing beneficial gut flora and easing GI side effects (nausea, diarrhoea, constipation, bloating). User-reported data highlights that 83% of GLP-1 patients saw noticeable improvement within 7–14 days of starting the supplement. Postbiotic compounds may also enhance GLP-1 and leptin production, aiding appetite regulation and metabolic function.
Improved gut comfort and reduced inflammation can encourage adherence to medications and dietary consistency.
Beyond GLP-1 users, the supplement may also support:
- Digestive processes (motility, nutrient absorption, reduced bloating)
- Intestinal barrier function and suppression of pro-inflammatory microbes (e.g. Klebsiella spp., C. difficile)
- Immune modulation via inflammation regulation
- SCFA production, aiding energy balance and appetite
- Positive gut-brain axis interactions supporting mental well-being
Summary: Digestive Comfort and Metabolic Balance
With a robust formulation and high stability, AZH-biotics® provides:
- Targeted relief from GI side effects linked to GLP-1 therapy
- Support for overall digestive and metabolic health
- Reliable potency and quality control for consistent results
- Enhanced therapy adherence and optimized wellness outcomes